Sign In
Buy IBB
$167.50
+3.23 (+1.97%)
At Close: Jun 03, 2026
Beyond Tech Industry: Here's how Biotech ETFs Are Riding the AI Wave
10:42am, Monday, 16'th Mar 2026
IBB and other biotech ETFs are gaining traction as AI reshapes drug discovery, genomics, and clinical trials, giving investors diversified exposure to biotech innovation.
Aster Capital Management DIFC Ltd Makes New Investment in iShares Biotechnology ETF $IBB
03:30am, Friday, 27'th Feb 2026
Aster Capital Management DIFC Ltd bought a new position in iShares Biotechnology ETF (NASDAQ: IBB) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commis
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
07:21am, Wednesday, 25'th Feb 2026
Designed to provide broad exposure to the Health Care ETFs category of the market, the iShares Biotechnology ETF (IBB) is a smart beta exchange traded fund launched on 02/05/2001.
Merit Financial Group LLC Trims Stock Holdings in iShares Biotechnology ETF $IBB
04:48am, Wednesday, 18'th Feb 2026
Merit Financial Group LLC lowered its position in shares of iShares Biotechnology ETF (NASDAQ: IBB) by 53.0% in the third quarter, according to the company in its most recent filing with the SEC. The
Should You Invest in the iShares Biotechnology ETF (IBB)?
07:20am, Tuesday, 17'th Feb 2026
Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the iShares Biotechnology ETF (IBB) is a passively managed exchange traded fund launched on February 5, 200
Revenge Of The Dividend Stocks
08:15am, Saturday, 07'th Feb 2026
Dividend stocks have sharply outperformed AI-related tech stocks since November 2025, reversing a multi-year trend. I see the rally in dividend ETFs like SCHD as overextended, prompting a pause in new
Florin Court Capital LLP Makes New Investment in iShares Biotechnology ETF $IBB
06:00am, Wednesday, 28'th Jan 2026
Florin Court Capital LLP acquired a new stake in iShares Biotechnology ETF (NASDAQ: IBB) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and E
This Wealth Manager Just Dumped Its Entire $3.5 Million Stake in the iShares Biotech ETF
11:25am, Tuesday, 27'th Jan 2026
Sold 24,270 shares of IBB; estimated trade value of $3.50 million based on quarterly average pricing. Net position value decreased by $3.50 million.
IBB: Beyond The 2025 Surge, Biotech Breakout
05:10am, Tuesday, 27'th Jan 2026
iShares Biotechnology ETF is rated a BUY, offering a balanced entry into biotech with large-cap stability and strong recent performance. IBB benefits from catalysts including accelerating M&A and AI-d
IBB: Biotech's Hot Streak May Cool
06:22am, Monday, 26'th Jan 2026
iShares Biotechnology ETF (IBB) earns a reiterated hold rating as it consolidates near all-time highs with balanced risk/reward. IBB's valuation is fair at a 19x P/E and low 3% EPS growth, resulting i
Nvidia–Eli Lilly Tie-Up Shows Why AI Drug Discovery Is The Next ETF Battleground
12:23pm, Wednesday, 14'th Jan 2026
NVIDIA Corp.'s (NASDAQ: NVDA) and Eli Lilly and Co.'s (NYSE: LLY) newly announced $1 billion AI co-innovation lab underscores how artificial intelligence is spreading beyond data centers into medicine
Funding for Risky Biotechs Is Returning
12:00pm, Monday, 12'th Jan 2026
Publicly traded drug developers sold more than $13 billion of shares in the fourth quarter, the most in more than four years.
SG Americas Securities LLC Has $4.13 Million Stock Position in iShares Biotechnology ETF $IBB
05:44am, Monday, 12'th Jan 2026
SG Americas Securities LLC lifted its holdings in shares of iShares Biotechnology ETF (NASDAQ: IBB) by 96.3% in the undefined quarter, according to the company in its most recent disclosure with the S
Commonwealth Equity Services LLC Sells 40,935 Shares of iShares Biotechnology ETF $IBB
03:51am, Saturday, 10'th Jan 2026
Commonwealth Equity Services LLC decreased its position in shares of iShares Biotechnology ETF (NASDAQ: IBB) by 22.7% in the third quarter, according to the company in its most recent 13F filing with
Here's Why Biotech ETFs Are Rallying Hard
11:01am, Friday, 09'th Jan 2026
Biotech rally gains steam on valuations, rate cuts, FDA wins & M&A. IBB, XBI, CANC and IDNA are ETFs near one-year highs.
